<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">The immunomodulatory drug lenalidomide combined with low-dose dexamethasone has shown promising efficacy and safety results [
 <xref ref-type="bibr" rid="CR8">8</xref>] and has been approved in EU for first-line treatment of non-transplant patients in February 2015. This regimen is also a backbone for combinations with carfilzomib, ixazomib, or elotuzumab [
 <xref ref-type="bibr" rid="CR14">14</xref>]. This may well pave the way for an alkylator-free new standard of care for elderly patients. It will be interesting to see the incorporation of these novel agents in routine practice and follow their effectiveness. Our successor cohort study, recruiting patients with MM in routine care in Germany was started in 2017 (
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> NCT03308474).
</p>
